Moderna Reveals ‘Positive’ Data In Coronavirus Vaccine Trial, Markets Spike

Boston biopharmaceutical Moderna announced Monday that “positive” data was collected from an early-stage human trial of a coronavirus vaccine, with all 45 participants producing COVID-19 antibodies⁠—and markets responded positively in pretrading hours, as the possibility of producing a vaccine against the virus moved one small step closer.